Preliminary Analysis Of A Us Phase Ii Study Of The Safety And Tolerability Of Proxalutamide (Gt0918) In Subjects With Mcrpc Who Had Progressed On Either Abiraterone (Abi) Or Enzalutamide (Enza).

Nicholas J. Vogelzang,Richard Levin,Arash Rezazadeh,Chandler H. Park,Britt Haley Bolemon,Nashat Y. Gabrail,Zulfiqar A. Malik,Luke T. Nordquist,Ashley Ross,Phoebe Zhang,Karl Zhou

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览7

暂无评分

摘要

99Background: GT0918, an androgen receptor (AR) antagonist, is a new chemical entity with reduced drug accumulation in the CNS. In a phase I dose escalation trial (NCT02826772), GT0918 was well tol...

查看译文

关键词

Androgen Receptor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要